Globus Medical (GMED) Tops Q1 EPS by 2c, Raises FY Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Globus Medical, Inc. (GMED) Reports Revenue Well Above Consensus, Brean Capital Note; PT to $33
May 6, 2015 7:13 AM EDTBrean Capital reiterates their Buy rating on Globus Medical, Inc. (NYSE: GMED) and raised the target price to $33 (from $30) after GMED posted revenues well above consensus. GMED's 1Q15 report showed and increase of 15.2% in revenues to $131.6 million. Despite lower margins, new products and... More
